Newsroom | 1301 results

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025, including new data from its global, double-blind, randomized, placebo-controlled Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assess...

AMERICAN FORK, Utah--(BUSINESS WIRE)--DOJ ASKS COURT TO DISMISS FTC-XLEAR LAWSUIT; Calls into Question FTC’s Authority to Require Clinical Studies for Non-Pharmaceutical Health Products...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink’s Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time. Webcast link can be found under Inve...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-...

HAYWARD, Calif. & TRAVERSE CITY, Mich.--(BUSINESS WIRE)--HealthBio (formerly IncellDx), an inflammatory disease diagnostic and therapeutic company, today announced it is pre-registering patients for its Phase III clinical trial to investigate the treatment of Long COVID/Post-Acute Sequelae of COVID (PASC) with Selzentry (maraviroc) and Lipitor (atorvastatin) tablets. The 32-week randomized, 252 patient, double-blind, placebo-controlled, multicenter study will evaluate the safety and efficacy of...

ST. LOUIS--(BUSINESS WIRE)--Gravity Diagnostics secures $5 Million investment from Advantage Capital to support critical diagnostic testing....

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2024. "IQVIA delivered excellent fourth quarter performance, closing out a strong 2024," said Ari Bousbib, chairman and CEO of IQVIA. "R&DS revenue was on target and bookings exceeded o...

BRISBANE, Australia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company advances its novel high-density microarray patch (HD-MAP) vaccine technology towards later stage clinical trials and commercialization. Dr. Emilio Emini, Dr. Nathalie Garcon, and Prof. Paul Young will join Vaxxas as consultants, providing clinic...

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), une société de Maravai® LifeSciences (NASDAQ : MRVI) et fournisseur mondial de réactifs et de services dans le domaine des sciences de la vie, vient d'établir un partenariat avec Avantor, Inc. (NYSE : AVTR), chef de file mondial des produits et services essentiels aux clients des secteurs des sciences de la vie et des technologies de pointe, afin d'étendre la disponibilité de ses produits innovants d'acide nucléique aux clients en...